Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 46OTHER_GOV 3INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 14Thoracic 10Gynecologic 8Genitourinary 6Breast 6Other hematologic neoplasm 4Lymphoid 4Myeloid 3Tumor-Agnostic 2Plasma cell 2Dermatologic 2CNS 2Sarcoma 1Other solid neoplasm 1Other neoplasm 1

Conditions

Osteosarcoma 1Neuroblastoma 1Glioblastoma 1

Interventions

Temozolomide 123Radiotherapy 47Bevacizumab 46Lomustine 25Radiation 20Nivolumab 17Irinotecan 16Carboplatin 16Cyclophosphamide 14Granulocyte-Macrophage Colony-Stimulating Factor 13pembrolizumab 11dabrafenib 10Trastuzumab 10Surgical Procedures, Operative 10Capecitabine 10paclitaxel-Angiopep-2 conjugate 8TIC10 compound 8Paclitaxel 8Gemcitabine 8Carmustine 8trametinib 7Topotecan 7IL13-PE38 7Everolimus 7Drug Therapy 7Aminolevulinic Acid 7AZD 6244 73-Iodobenzylguanidine 7fludarabine 6enzastaurin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Blood Specimen Collection × CNS × Clear all
NCT03860207 2023-09-13

Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers

Y-mAbs Therapeutics

Phase 1/2 Terminated
12 enrolled 15 charts
CNSSarcoma

Neuroblastoma, Osteosarcoma

NCT01071837 2015-06-16

APG101 in Glioblastoma

Apogenix AG

Phase 2 Completed
84 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡